We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    RO7204239
Previous Study | Return to List | Next Study

A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05548556
Recruitment Status : Recruiting
First Posted : September 21, 2022
Last Update Posted : January 9, 2023
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD).

Condition or disease Intervention/treatment Phase
Facioscapulohumeral Muscular Dystrophy (FSHD) Drug: Placebo Drug: RO7204239 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy
Estimated Study Start Date : January 13, 2023
Estimated Primary Completion Date : June 15, 2024
Estimated Study Completion Date : December 15, 2025


Arm Intervention/treatment
Placebo Comparator: Placebo
Participants will complete a 4-week pre-treatment period to collect baseline movement data with a wearable device, then receive subcutaneous (SC) placebo every 4 weeks for 52 weeks. After the treatment period, participants will have the option to receive RO7204239 for an additional 52 weeks.
Drug: Placebo
Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)

Experimental: RO7204239
Participants will complete a 4-week pre-treatment period to collect baseline movement data with a wearable device, then receive SC RO7204239 every 4 weeks for 52 weeks. After the treatment period, participants will have the option to receive RO7204239 for an additional 52 weeks.
Drug: RO7204239
Participants will receive SC RO7204239 Q4W




Primary Outcome Measures :
  1. Percent change from baseline in contractile muscle volume (CMV) of quadriceps femoris muscles as assessed by magnetic resonance imaging (MRI) bilaterally [ Time Frame: Week 52 ]
  2. Percentage of participants with adverse events (AEs) [ Time Frame: Up to 2.5 years ]

Secondary Outcome Measures :
  1. Change from baseline in serum concentration of total latent myostatin [ Time Frame: Through 2 years ]
  2. Change from baseline in serum concentration of free latent myostatin [ Time Frame: Through 2 years ]
  3. Change from baseline in serum concentration of mature myostatin [ Time Frame: Through 2 years ]
  4. Percent change from baseline in CMV of 36 muscles based on whole body MRI [ Time Frame: Weeks 28 and 52 ]
  5. Change from baseline in fat fraction of 36 muscles based on whole body MRI [ Time Frame: Weeks 28 and 52 ]
  6. Percent change from baseline in CMV of quadriceps femoris muscles as assessed by MRI bilaterally [ Time Frame: Week 28 ]
  7. Change from baseline in fat fraction of quadriceps femoris muscles as assessed by MRI bilaterally [ Time Frame: Weeks 28 and 52 ]
  8. Percent change from baseline in CMV of tibialis anterior muscles as assessed by MRI bilaterally [ Time Frame: Weeks 28 and 52 ]
  9. Change from baseline in fat fraction of tibialis anterior muscles as assessed by MRI bilaterally [ Time Frame: Weeks 28 and 52 ]
  10. Percent change from baseline in CMV of biceps brachii muscles as assessed by MRI bilaterally [ Time Frame: Weeks 28 and 52 ]
  11. Change from baseline in fat fraction of biceps brachii muscles as assessed by MRI bilaterally [ Time Frame: Weeks 28 and 52 ]
  12. Percent change from baseline in contractile cross-sectional area (CSA) of skeletal muscle in the proximal lower limb muscles as assessed by MRI bilaterally [ Time Frame: Weeks 28 and 52 ]
  13. Change from baseline in fat fraction of proximal lower limb muscles as assessed at a single mid-femur slice bilaterally by MRI [ Time Frame: Weeks 28 and 52 ]
  14. Serum concentration of RO7204239 [ Time Frame: Through 2 years ]
  15. Maximum serum concentration (Cmax) of RO7204239 [ Time Frame: Through 2 years ]
  16. Area under the concentration-time curve (AUC) of RO7204239 [ Time Frame: Through 2 years ]
  17. Trough concentration (Ctrough) of RO7204239 [ Time Frame: Through 2 years ]
  18. Percentage of participants with anti-drug antibodies (ADAs) [ Time Frame: Baseline up to approximately 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Genetic confirmation of FSHD1 or FSHD2
  • Clinical findings consistent with FSHD
  • Ability to walk unassisted
  • Ricci Clinical Severity Scale score ≥ 2.5 and ≤ 4
  • Agreement to maintain the same frequency and intensity of physiotherapy, occupational therapy, and other forms of exercise during the clinical study

Exclusion Criteria:

  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 17 months after the final dose of RO7204239
  • Current or previous treatment (or receipt) of anti-myostatin therapies
  • Treatment with any investigational therapy within 90 days prior to screening, or 5 drug-elimination half-lives of the drug, whichever is longer
  • Contraindications to MRI scans
  • Presence of clinically significant ECG abnormalities
  • Presence of clinically significant cardiovascular disease
  • Presence of clinically significant abnormal findings in echocardiography at screening, with the exception of mitral valve prolapse, which does not exclude participants from the study
  • Any major illness within 1 month before screening
  • Ascertained or presumptive hypersensitivity (e.g., anaphylactic reaction) to RO7204239, or to the constituents of its formulation
  • History of malignancy (except in situ basal cell carcinoma of the skin and in situ carcinoma of the cervix of the uterus that have been excised and resolved with documented clean margins on pathology)
  • Any clinically relevant history of anaphylactic reaction requiring inotropic support
  • Any abnormal skin conditions, pigmentation, or lesions in the area intended for SC injection (abdomen) and that would prevent visualization of potential injection-site reactions to RO7204239
  • Immobilization, surgical procedures, fracture, or trauma to the upper or lower limbs within 90 days prior to screening or longer, if judged by the investigator that it may affect motor function assessment
  • Any planned surgery that may affect a participant's motor function assessment, including participants who have had surgery of scapular fixation within the 12 months preceding screening or that are planned during the study
  • Use of the following medications within 90 days prior to enrollment: salbutamol or another β2-adrenergic agonist taken orally; creatine; recombinant human growth hormone; recombinant human insulin growth factor-1; testosterone, oxandrolone, or other anabolic steroid; chronic oral or parenteral use of corticosteroids (inhaled corticosteroid use is allowed) unless required to manage injection reactions;agents anticipated to increase or decrease muscle volume or strength

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05548556


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: BN43703 https://forpatients.roche.com/ 888-662-6728 global-roche-genentech-trials@gene.com

Locations
Layout table for location information
Denmark
Rigshospitalet; Klinik for Nerve- og Muskelsygdomme Recruiting
København Ø, Denmark, 2100
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT05548556    
Other Study ID Numbers: BN43703
First Posted: September 21, 2022    Key Record Dates
Last Update Posted: January 9, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Dystrophy, Facioscapulohumeral
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn